NCT05778149View on ClinicalTrials.gov

Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2023

Primary Completion Date

March 31, 2025

Study Completion Date

March 31, 2027

Conditions

AumolertinibAnlotinibTP53NSCLCEGFR Activating Mutation

Interventions

DRUG

Aumolertinib,Anlotinib

Aumolertinib 110mg p.o QD; Anlotinib 12mg, oral for 2 weeks, three weeks a cycle, until disease progression.

All Listed Sponsors

lead

Tianjin Medical University Cancer Institute and Hospital

OTHER

NCT05778149 - Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation | Biotech Hunter | Biotech Hunter